Health Breaking News 330

Health Breaking News Links, as part of the research project PEAH (Policies for Equitable Access to Health), aim to focus on the latest challenges by trade and governments rules to equitable access to health in resource-limited settings

Health Breaking News 330

 

State of emergency: UN convenes Financing Forum while a new wave of debt crises threatens to derail sustainable development 

WHO Seeks To Strengthen Partnerships, Improve Financing For “Triple Billion” Targets 

Greater transparency, fairer prices for medicines ‘a global human rights issue’, says UN health agency 

WHO-led Fair Pricing Forum Gathers Diverse Groups To Improve Drug Access 

2019: USTR takes aim at European countries over pharmaceutical pricing and reimbursement policies 

USTR 2019 National Trade Estimate Report on Foreign Trade Barriers 

Lack of Access To Antibiotics Is A Major Global Health Challenge 

GARDP announces partnership with Calibr, HZI/HIPS and the University of Queensland in search for new antibiotics 

Broken drug markets in infectious diseases: Opportunities outside the private sector? 

New Cancer Therapies Are Great—But Are They Helping Everyone? 

Forum steers the search for a ‘fair price’ for cancer medication 

Greece: MSF uses ‘Humanitarian Mechanism’ for first time in Europe due to high price of pneumonia vaccine 

Statement on the meeting of the International Health Regulations (2005) Emergency Committee for Ebola virus disease in the Democratic Republic of the Congo on 12th April 2019 

MSF: Ebola epidemic not under control, urgent change of strategy needed 

DRC Ebola: Latest numbers as of 15 April 2019 

Evidence Shows Ring Vaccination Strategy Effective In Limiting Ebola Outbreak In DRC 

Measles cases are up nearly 300% from last year. This is a global crisis 

Challenges and opportunities for control and elimination of soil-transmitted helminth infection beyond 2020 

DNDi and Atomwise Collaborate to Advance Drug Development Using AI for Neglected Diseases 

WHO releases first guideline on digital health interventions 

Human Rights Reader 479 

Nicaragua’s human rights crisis requires international response 

Flawed conditions: the impact of the World Bank’s conditionality on developing countries 

Plummeting aid figures fail to meet spending target while leaving poorest behind 

How Grand Rapids, Michigan, Is Using Data To Advance Health Equity And Economic Opportunity 

Outdated registry information makes it hard for patients to join clinical trials 

Can young people change the national conversation about refugees? 

The financial sector must be at the heart of tackling climate change 

Climate change ‘could slash Brazil’s maize yields’ 

The Good, The Bad and The Dirty 

Greta Thunberg urges MEPs to ‘panic like the house is on fire’ 

Climate change will be key issue in EU elections, poll shows 

Why Public Health Care is Better

Viva Salud is a Belgian NGO that supports movements for health in the Philippines, Palestine and DR Congo. Recently, they launched the paper Why Public Health Care is Better  with the aim to debunk long lasting myths concerning the commercialisation of health care

 By Julie Steendam

Policy Officer on Health, Viva Salud

Brussels, Belgium

 Why Public Health Care is Better

 

This article is a summary of the paper
 Why Public Health Care is Better
 We hope that this paper can be a support for those social movements standing up for social justice

 

 The majority of countries in the world agreed to take all possible measures to fulfil the right to accessible and qualitative health care for their population. However, year 2019, this is far from achieved. Even worse, many national governments and international institutions direct health policies along a market-led approach. Privatisations have been brought up as the solution to national health systems’ funding shortages. But numerous case studies and comprehensive research show that health outcomes get worse when the pursuit of profit comes in:

Privatisation triggers higher inequality in access to care
Private hospitals have to make a profit, so they focus mainly on people who can afford it. This creates the risk of a health system at two speeds. On the one hand, high-tech and specialised care for the rich and, on the other hand, simple public health care for the less well-off. This despite the fact that it is the duty of public service providers to provide care to everyone, without distinction.

Privatisation is often more expensive in the long run
Unexpected costs, such as rising interest rates or expensive energy prices, are usually passed on to the government or the patient in private hospitals. An Oxfam study calculated that a public-private hospital in Lesotho costs the government three times more than the public hospital it replaced. Under some contracts, the company can even sue the state for costs related to protests of employees.

Privatisation isn’t more efficient
Public systems are more efficient because they ensure economies of scale in the purchasing, supply and distribution of drugs and equipment.
By contrast, in the United Kingdom, the number of managers in the National Health Service tripled since the introduction of a market logic. In the Netherlands, private health insurers spend 500 million euros per year on advertising campaigns.

Privatisation doesn’t lead to better quality
In today’s market logic, private institutions will focus on the treatments that are financially interesting, instead of those that benefit the patient the most. In Peru, private hospitals are much more likely to choose a more risky caesarean section than a natural birth, because the doctor can charge more.

Privatisation leads to less public control
Negotiations between private players often take place under strict rules of confidentiality. Public control is therefore very difficult, which makes the risk of corruption increase. Engaging funds from the private sector opens the way for corporate involvement in policy shaping.

Privatisation leads to a lower availability of health workers and deteriorating working conditions for them
Commercial companies take the scarce resources, such as health workers, away from the public sector. This so-called “brain drain” leads to shortages in the public sector and in more remote areas. Moreover, the drive for ever higher profit margins often leads to poorer working conditions, unpaid overtime and higher work pressure. Burn-out and stress symptoms are very common in the health sector.

The alternative exists

This paper starts from the positive side. All over the world, social movements and governments make efforts to change their health care system for the benefit of the population.

Universal access to quality health care is a feasible political choice

Countries that prioritise people’s well-being and choose to invest in making health care accessible to all achieve better health outcomes. Even countries with low expenditure on health have been able to build strong health systems.

Need, not wealth

The only proven route to realise this is cancelling all fees for health care and essential medicines, and increasing public investments in well-trained staff, nearby health facilities, and prevention and health promotion programs. A unified public system does not have the disadvantageous contradictions brought by the fragmentation and competition that characterises mixed private-public health systems.

What the international community can do

Reinforcing countries financial capacities to cope with a potential budget increase should also be a focus of the international community and international institutions, for example by

– stepping away from imposed budget restrictions in public services

– regulating pharmaceutical companies’ monopoly positions

– cancelling debt

– fighting large-scale tax evasion

– excluding health services from trade and investment agreements.

Due to globalisation, the vast majority of people in the world are subjected to very similar economic realities, forces and dynamics: environmental degradation, the global competition of workers, attacks to and exclusion from social protection schemes and a growing inequality between social classes to name but a few.[i]

This global emergency situation represents an unprecedented challenge for humanity. Since health and other societal challenges are very interconnected, the struggle for health can function as a major unifying factor in the mobilisations required to address these issues.

——————————

[i] The Struggle for Health, 2018, p.2

Health Breaking News 329

Health Breaking News Links, as part of the research project PEAH (Policies for Equitable Access to Health), aim to focus on the latest challenges by trade and governments rules to equitable access to health in resource-limited settings

Health Breaking News 329

 

Universal Health Coverage – World Health Day Theme Reflects Diverse Agendas 

WHO urges stronger action to reduce deaths from noncommunicable diseases in Europe by one third  

Opinion: 5 priorities for the World Bank’s new leader 

Eurodad response to selection of David Malpass as the new president of the World Bank Group 

Neoliberalism promised freedom – instead it delivers stifling control 

The IMF and PPPs: A master class in double-speak 

Contributing to a Healthier World, Interview with Ilona Kickbusch 

Taking a complexity perspective when developing public health guidelines 

USMCA Agreement and the Remedies for Patent Infringement 

Comment on Damages provisions in USMCA IP Chapter, as regards biologic drugs, and patents on surgery and medical procedures 

AFEW Creates Space for Public Health Within EU-Russia Civil Society Forum by Valeria Fulga 

The Italian Investor Proposed USD 379.7 Million Lubowa Hospital Construction Project in Uganda by Michael Ssemakula and Denis Bukenya 

Biosimilars Are A Distraction 

Can Transparency Lower Prices and Improve Access to Pharmaceuticals? It Depends 

Immunization programmes and notifications of vital events 

HIV/AIDS Quiz  

Combating cholera in Mozambique 

Window screens ‘could reduce global malaria burden’ 

Eye care for Ebola survivors 

DRC Ebola: latest numbers as of 8 April 2019 

Why British universities are now racing to post their clinical trial results 

Using Policy Levers To Reduce Sugary Drink Consumption 

UNFPA: State of World Population 2019 

Human Rights Reader 478 

Global Life Expectancy Improved, Women Outlive Men, But Gaps Persist Based On Income 

India’s Integrated Child Development Services programme; equity and extent of coverage in 2006 and 2016 

Next UN Food Chief Must Tackle Hunger ‘Emergency’ 

“We Need to Build Power to Win.” A Fund for Climate Justice is Gaining Momentum 

Green Intermediaries: The Pooled Funds Connecting Donors to the Frontlines of Climate Change 

The Amazon Seeks Alternatives that Could Revolutionise Energy Production 

Development-bank climate funds seek new dollars, as competition heats up 

 

 

 

 

 

 

 

 

 

 

Health Breaking News 328

Health Breaking News Links, as part of the research project PEAH (Policies for Equitable Access to Health), aim to focus on the latest challenges by trade and governments rules to equitable access to health in resource-limited settings

Health Breaking News 328

 

WHO: Public Health Round-up 

Major UN Effort To Achieve Universal Health Coverage Taking Shape 

Does health matter in the European Parliament elections? 

EU leadership needs to embed human rights into economic policy-making 

Disease costs Africa an ‘astounding’ $2.4 trillion in lost productivity every year 

Noncommunicable disease burden among HIV patients in care: a national retrospective longitudinal analysis of HIV-treatment outcomes in Kenya, 2003-2013  

KEI statement: 22nd meeting of the WHO Expert Committee on the Selection and Use of Essential Medicines 

Mirfin Mpundu: accessing medicines, fighting resistance 

Evidence needed for antimicrobial resistance surveillance systems 

Tuberculosis drugs’ distribution and emergence of resistance in patient’s lung lesions: A mechanistic model and tool for regimen and dose optimization 

Cyclone Idai: First cholera death in Mozambique as cases double 

Cholera Is Spreading in Mozambique, and It’s Far From the Only Health Threat 

Louisiana’s Journey Toward Eliminating Hepatitis C 

DRC Ebola: latest numbers as of 2 April 2019 

An Epidemic of Suspicion — Ebola and Violence in the DRC 

Study: Many in Ebola outbreak don’t believe virus is real 

Faster and cheaper test to detect Zika 

Global expansion and redistribution of Aedes-borne virus transmission risk with climate change 

Widely Used Public Health Surveys May Underestimate Global Burden of Childhood Diarrhea 

Estimates of number of children and adolescents without access to surgical care 

Uneven access to health services drives life expectancy gaps: WHO 

European Regional Forum on Education, Language and Human Rights of Minorities. European Parliament, Brussels, 6-7 May 2019 

Most SDGs ‘going into reverse’ – UN expert group member  

After a decade of action on health inequalities, is it time for a new approach? 

WHO Symposium puts Health Inequalities at Centre of Digitalisation in Healthcare 

Empowering women in rural Nepal: My journey from Nepal to Stanford (and back) 

Rewriting history: Caring for children trapped in an island prison 

Acute hunger hits 113 million people, but data gaps remain 

Air Pollution Lops Nearly 2 Years Off Global Life Expectancy 

Ocean heat hits record high: UN 

 

AFEW Creates Space for Public Health Within EU-Russia Civil Society Forum

PEAH is pleased to help circulate a message by partner organisation AFEW International regarding the newly initiated Working Group (WG) on Public and Inclusive Health within the EU-Russia Civil Society Forum. Those organisations that are interested in joining AFEW’s WG can get in touch with AFEW’s director of programs and WG’s coordinator Janine Wildschut at janine_wildschut@afew.nl

By Valeria Fulga

AFEW International

AFEW Creates Space for Public Health Within EU-Russia Civil Society Forum

 

AFEW International initiates the Working Group (WG) on Public and Inclusive Health within the EU-Russia Civil Society Forum. AFEW is doing it together with the following organisations: Active Citizenship, Stichting Skosh, Centre for Social Support “Navigator”, FOCUS-MEDIA Foundation, Humanitarian Action, Humanitarian Project, Kovcheg Anti-AIDS. AFEW felt the need of introducing a completely new topic to the Forum after participating in various General Assembly meetings of the Forum.

Having a healthy society stands at the very base of any nation. Health related issues arise not only within health-related policies, but also at various other levels.

AFEW International sees deteriorations in Romania, Bulgaria and Russia when it comes to the freedom of speech and implementation of social justice work in the light of health field. Working in solidarity with European Union and Russia Civil Society Organisations towards inclusiveness, particularly when it comes to health is what AFEW aims for in this WG.

“More precisely, the present WG aims to learn from other Civil Society Organisations what methods worked for them and we – the members of the WG – would like to use it as an exchange platform and understand how other countries are working on an inclusive health agenda and how they are resilient in difficult times.” says Janine Wildschut, coordinator of the WG.

AFEW International has already gathered a group of active community-led civil society organisations in the WG. These organisations have a background in HIV or key populations fields. During the General Assembly which will take place in Bratislava in May 2019, several meetings will be organised. These meetings will have two different objectives: discussing the path for the WG and opening the WG for other interested parties.

Those organisations that are interested in joining AFEW’s WG can get in touch with AFEW’s director of programs and WG’s coordinator Janine Wildschut at janine_wildschut@afew.nl

 

The Italian Investor Proposed USD 379.7 Million Lubowa Hospital Construction Project in Uganda

Uganda needs only USD 9.6 million to put its Mulago national referral hospital to an internationally recommended standard, the proposed USD 379.7 million can construct five state-of-art cancer hospitals with 1000 bed capacity each. But why would the government instead opt for a USD 379.7 million deluxe hospital that has a bed capacity of only 264 which will benefit a handful?! Is this the best approach to set our line-of-preferences at the cost of other numerous districts without a single public hospital?

 By Michael Ssemakula

and Denis Bukenya

Health Rights Advocates

Human Rights Research Documentation Center (HURIC), and PHM-Network, Uganda

The Italian Investor Proposed USD 379.7 Million Lubowa Hospital Construction Project in Uganda

Disconnections and Disruptions in the Health Sector Expenditure Priorities

Disclaimer: PEAH disclaims and refuses any responsibility for the views expressed in this article which are solely those of the authors and do not engage Policies for Equitable Access to Health

 

Uganda has increasingly incorporated the neoliberal capitalistic forces in providing, financing and developing state health infrastructure and service delivery through public–private synergies. Justifications for this commitment are diverse stretching from levitation of finance for maintaining and operating public health to assistance for the high-end investment functions and scaling-up support for ever growing GDP expenditure to lessen the budgetary gap. Though Public Private Partnerships (PPPs) are a magnetization  propulsion to an enormous segment of the civil corporate powers and diverse stratified clusters of stakeholders in state possessed and managed entities in Uganda, over two decades ago, there is still absentia of a sturdy thrust impulsion of a mechanism to draw and incorporate well streamlined and rationalized strategic policy charters in the health management in which state and non-state nexus in health service provision is well regulated to effectively improve healthcare delivery even in the marginalized and impoverished settings.

In a paper by (Denis Bukenya, 2019), the elementaristic and contemporary forces of governance for health have superseded the humanlike social-progressive provision of state centric health services with the mixed hegemony of capitalistic health service provision through which the competitive commodified health system has emanated. There is limited significance, conceptualization and in-depth investigation about the PPP phenomenon’s implications on the Uganda’s health sector among the resource apportioning powers— which has culminated into a simultaneous backwash quantum of adversely skewed anthropologic socio-economic inequality space, eccentric complex aligned health priorities, negligent privatization of the fundamental public services and one-sided investment trade agreements predominantly through the multi-national business conglomerates’ treaties. But is this a sustainable roadmap to attain the UHC commitments?

Achieving universal health care (UHC) is a health priority entrenched in the Sustainable Development Goals. Though there is no one-size fits all model for universal health care in all settings, the ultimate health system approach would be one that is people-centered, rights-based, integrated, non-biased, and broadly-inclusive in all its processes and priority setting to build an egalitarian mechanism of healthcare delivery.

The power arm, policy orchestras and policy enhancing actors in the government quite often blame the insufficient public health funding on poverty. But the actual culprits are inappropriate misplaced priorities and corruption —few state managers in Uganda prioritize health over private actors’ big businesses and civil corporate elite interests. Bettering the lives of the privileged affluent classes and devoting exorbitant sums of money towards frivolous expenditures to political party financing is now a genealogistic and an indirectly legalized abnormally normalized health rights violation in Uganda. A common practice that is undermining health. This is unsympathetically intensified by the pseudo “public” white elephant projects, laced first in the scale of the ostentatious and flamboyant priorities at the expense of adequate health, education, and other services that would improve the social-economic welfare of the citizenry.

Besides the government of Uganda insensitively spending over USD 48 million on a private presidential jet by 2014, (Tomori, 2014), in February 2019 a hardcore, egocentric, ruthless and  merciless bunch-of-crooked mafias of the governing body, shamelessly came up with another worse than ever anti-humancentric mockery to Ugandans through another over-and-above excessively inflated unscrupulous multi-million dollar Italian investor hospital project, an attack on the poor country’s ever hemorrhaging empty coffers.   On 12th of March 2019, the parliament and the National Economy Committee approved a promissory note of USD 379.7 million which will be given to an Italian private investor. Through a loan request, the government seeks to borrow USD 379.7million (UGX 1.3 trillion, which is more than half the Uganda’s projected health expenditure for the Financial Year 2019/2020) that will be given to this little-known investor to construct the hospital that government says will be for the treatment of Non-Communicable Diseases (NCDs). In reports by (Okello, 2019) and (Independent, 2019), the documents that were submitted by the Ministry of Finance and Economic Development, the total project cost breakdown is USD249.9 million excluding tax payment component. However, the financing for which government is seeking the Legislatorial approval is USD379.7 Million thus an increment of USD 129.83 million, which is 52% of the original projected cost.

The report by (Network, 2019) shows that the Parliament doesn’t know the investor-in-question to be assigned this work. The hospital is to be constructed under a corporation between FINASI and ROKO Construction Ltd. Ugandans know ROKO and its operations in Uganda, but greater majority are not in the know of FINASI. FINASI was registered in Italy in 1993 but on their website https://finasi.com/ , FINASI was established and started its operations in the 1969. The company was founded as a 360° Importer/Exporter and a primary goods trader in the Middle East and far as Africa. FINASI is basically an import/export company in mineral ores, quarried stone, furniture, clothing and footwear, paper, chemicals, industrial machinery, agricultural machinery, toilet systems and so on. The company has diverse activities it deals with but has no phone numbers on its website which conclusively make us suspicious of this, an eminent scam danger. Apart from a mention of surgical equipment and instruments; hygiene and sterilization equipment for medical and surgical use, there is no indication that FINASI has any experience or footprints in establishing a hospital. The company type is registered as a head office! This is unquestionably a fraud trouble Ugandans are likely to befall, the 1989 year of establishment contradicts with the year 1969 in which it claims to have been registered. CF (Codice Fiscale): 01139180937 Registration No.: PN 45691. All companies in European Union are required by law to submit the total financial annual returns and there is no information about FINASI past 2015. In Europe, no bank or government can guarantee companies like FINASI without a transparent annual audited return filed with the Italian government in this case. The company turnover is 2-5 million Euros from 2013-2015 which sounds phony, and a total deception because the companies in Europe submit total financial annual returns and there is no information about FINASI past 2015. There are no records for the financial years 2016, 2017, 2018. Enrica Maria Aristidina Pinetti, is the CEO – Chief Executive Officer (Ceo – Amministratore Delegato). There are no any other staff or vice president listed. The company is listed to have nine staff and yet it claims to have operations in Italy, far as east, Russia, Middle East and sub-Saharan Africa.

Worse still there is no secured land for this above-life health facility, the land on which the project is to be allocated is under dispute by a Buganda Royal family. This implies that the said land’s legal status is still unsettled, therefore we risk litigation and we might be subjected to another drama of a multi-million dollar humiliating frenzy-of-penalization after the investment kick-start.

Despite of the efforts to fight the disease in Uganda to achieve the SDGs’ 2030 agenda, and also meet the universal commitments enshrined in the global guiding instruments such as the Article 25 of UDHR, 1978 Alma Ata declaration, the 2001 Abuja declaration and the 2018 Astana declaration, Uganda still faces a horrific nightmare of poor misguided and non-inclusive priority setting processes in the health sector. Uganda needs only USD 9.6 million to put its Mulago national referral hospital to an internationally recommended standard, the proposed USD 379.7 million can construct five state-of-art cancer hospitals with 1000 bed capacity each. But why would the government instead opt for a USD 379.7 million deluxe hospital that has a bed capacity of only 264 which will benefit a handful?! Is this the best approach to set our line-of-preferences at the cost of other numerous districts without a single public hospital?

The question of inadequacies in the Uganda’s health governance is an outrageous dark-fortune that still stand vividly. The enabling arm through the decision powers of the independent institutions is unwaveringly being emasculated through one decision enhancer, the president and the common jargon of ‘orders-from-above!’ Governance for health in this sense in regards to oversight, control, transparency, responsiveness, equity, effectiveness, efficiency, regulatory quality, accountability, consensus orientation and participatory priority setting process in-line with objectives, and interests of institution’s management and public health strategies has lost its course. Therefore to prevent wasteful expenditures, we must have well streamlined, rationalized and efficient health strategies that clearly describe and guide the procedures within institutions (notably government) and define priorities and the parameters for action in response to the public health needs and available resources. This should be properly incorporated with inclusive approaches which embrace social responsibility through community engagement and increase in investments for health development through participatory processes.

 

References

Denis Bukenya, &. Michael Ssemakula. (2019). The Rhetoric In Achieving The Universal Health Coverage Under Public-Private Partnerships In Uganda. PEAH.

Financing, D. o. (2012). Health Systems Governance for Universal Health Coverage. Geneva: World Health Organization.

Independent, T. (2019, February 13). MPs query $379M Gov’t support to Lubowa hospital investor. Kampala, Central, Uganda.

Kickbusch, I. (2014). A new governance space for health. Global Health Action, Issue 6.

Network, U. D. (2019, March 20). Here is what Ugandans need to know about FINASI. Kampala, Central, Uganda.

Okello, G. (2019, March 12). Parliament approves UGX1.3 trillion loan for Lubowa hospital amid land dispute with royal family. Kampala, Central, Uganda.

Tomori, O. (2014). Health in Africa: Corruption and misplaced priorities. Kampala: Bulletin Daily.

 

 

Health Breaking News 327

Health Breaking News Links, as part of the research project PEAH (Policies for Equitable Access to Health), aim to focus on the latest challenges by trade and governments rules to equitable access to health in resource-limited settings

Health Breaking News 327

 

Access To Essential Medicines – Charles Gore Speaks About MPP’s Expanding Role 

After Shutdown, Prompt Implementation Of FDA Plan To Combat Antibiotic Resistance Is Critical 

44 African countries plan for effective implementation of new WHO TB guidelines  

UNAIDS Reports Mixed Progress Towards Reaching The 2020 Target Of Reducing TB Deaths Among People Living With HIV By 75% 

The Inability of the Patent System to Reward Innovation by Public Actors: the Bedaquiline Example by Barbara Milani 

Building tuberculosis awareness in low-risk countries 

TDR collaborations build regional networks and research capacity to fight TB 

Breaking the cycle: Paediatric DR-TB detection, care and treatment in Tajikistan 

It’s Time to End TB in EECA Countries by Helena Arntz and Olesya Kravchuk 

The U.S. Government and Global Tuberculosis Efforts 

WHO Calls For International Support After Ebola Infections Rise In DRC 

DRC Ebola: latest numbers as of 25 March 2019 

Missing the mark? PEOPLE IN EASTERN DRC NEED INFORMATION ON EBOLA IN A LANGUAGE THEY UNDERSTAND A RAPID LANGUAGE NEEDS ASSESSMENT IN GOMA, DRC 

Diarrhoea kills more children in war zones than war itself – Unicef 

Measles vaccination: A matter of confidence and commitment 

At A Post-Gottlieb FDA, What Does The Future Hold For Public Health? 

New report: 25 major U.S. medical universities violate key transparency law 

Poor lose out as rich countries link aid with trade: think-tank 

Turbulences in Uganda’s Global Aid Construct: Is the Contemporary Aid Effective Enough to Transform Uganda’s Health System to Achieve UHC? by Michael Ssemakula 

Is CDC doing enough to ‘make tackling poverty its top priority’? 

Human Rights Reader 477 

Who Is Funding Solutions to the Root Causes of Mexican and Central American Migration? 

US expands abortion ‘gag rule,’ cuts funding to the Organization of American States 

ACADEMICS FOR PEACE: A BRIEF HISTORY Human Rights Foundation of Turkey (HRFT) Academy, March 2019 

How Political Correctness Can Change Society’s Views On Mental Health by Tiffany Osibanjo 

Is Wealth Good for Your Health? Some Thoughts on the Fateful Triangle of Health by Iris Borowy 

Stiglitz urges joint EU-China trade sanctions against the US on climate change 

EU on track for 50% emission cuts by 2030, study says 

Q&A: Guyana’s Roadmap to Become a Green State 

L’impronta ecologica delle strutture e dei servizi sanitari 

The Inability of the Patent System to Reward Innovation by Public Actors: the Bedaquiline Example

An impressive number of public actors are sponsoring and collaborate on Phase II/III trials and observational studies for the development of shorter, more effective regimens for Drug Resistant Tuberculosis (DR-TB), including the new chemical entity bedaquiline. The evidence accrued from these studies is being used by WHO to develop treatment guidelines. It will likely be used by stringent regulatory agencies to grant full registration status to bedaquiline. Despite important public investments, the accessibility of bedaquiline is a major concern for the implementation of the new WHO guidelines for DR-TB treatment and for public health strategies to tackle tuberculosis. Can public actors claim rights over their investments in and contribution to innovation?

By Barbara Milani

Independent Consultant, Pharmaceuticals and Public Health – Programme & Policy Specialist

The Inability of the Patent System to Reward Innovation by Public Actors: the Bedaquiline Example  

 

With WHO recommending bedaquiline as a priority medicine for the treatment of Drug Resistant Tuberculosis (DR-TB) in August 2018, a renovated call for access has mobilized patients, the global health community and civil society to gain access to this life-saving medicine. (1,2)

The bedaquiline story adds a new dimension to the debate of the past 20 years on the patent system and its inability to foster innovation to meet public health needs. Several commissions, working groups and processes have been established within the United Nations umbrella, yet with no tangible reform of the governance system for Research and Development. The last attempts are represented by the WHO Consultative Expert Working Group on Research and Development (CEWG) and by the UN Secretary-General’s High-Level Panel on Access to Medicines.

Bedaquiline was developed by Janssen Pharmaceuticals for the treatment of DR-TB in a stand-alone mode only up to Phase II trial level. The development of the innovator company has allowed for its ‘conditional registration’ in the USA and Europe as an add-on medicine to the toxic cocktail of old medicines in a 24-months DR-TB regimen with an efficacy of around 50%. The ‘conditional registrations’ were provided by the US FDA and the EMA based on Janssen’s Phase IIb results. Subsequently, the US FDA requested Janssen to proceed to a Phase III trial of bedaquiline as part of a new shorter less toxic regimen for DR-TB in order to proceed to a full registration of the medicine. (3) At this point in the story, an impressive amount of public actors and hence public investments come into play to trial bedaquiline as part of new shorter and more effective DR-TB regimens.

Bedaquiline is being studied in at least 8 Phase II and III trials by over 10 public actors as main sponsors (scientific organizations, state research institutions, NGOs, not-for-profit organizations, academic institutions) in over 25 countries. An uncountable number of public institutions are collaborators of the main sponsors of these trials. South Africa presents more than 12 clinical trial sites in public hospitals and TB clinics studying bedaquiline in different regimens. (4) Public actors are also conducting several observational studies in different countries, which contribute to produce evidence on the use and safety of the medicine as part of new regimens for DR-TB. The WHO recommendations on the use of bedaquiline as a priority medicine for new DR-TB regimens are based on evidence produced through the impressive mobilisation and investment by public actors. (5,6)

Janssen Pharmaceuticals holds on to its patents to maintain exclusive price control on bedaquiline as in the usual schemes of private product development and market control. (5, 7) Bedaquiline is widely patented in several middle and low income countries. The filed and granted patents include process patents, patents on the compound family, on the salt of the medicine, on the use of the medicines to treat DR TB and latent TB. Patent expiry for bedaquiline is due some time between 2023 and 2028, thereby providing Janssen with exclusive price control until patent expiry in countries. (8) The company has applied tiered pricing to bedaquiline for public health programmes since the medicine’s conditional registration. The lowest tiered price now applied by Janssen is 400 USD for six months of treatment. This is still a significantly high price for the new WHO-recommended DR-TB regimens. The medicine is available at much higher prices in the Russian Federation and in other middle income countries, making it virtually impossible for countries to implement the new WHO recommendations. (5,6) Civil society organizations and TB activists have filed a patent opposition in India to facilitate generic competition and reduced prices. (9)

There is an additional element that the global health community should consider beyond playing by the patent system. The current governance system for new health technologies largely based on the patent system fails to reward the investments made by public actors as well as to balance public financial incentives for product development. (5)

The US FDA has requested Phase II and III trials in order to proceed to the full registration of bedaquiline.  The public entities involved in these trials, including the hosting countries, should request for a reward on their invested resources to the company.  Hence, legal actions should not only target the shortfalls of the patent system to provide access to this life-saving medicine, but should also address in other venues a recognition of the public investments to reach full registration for an improved indication of bedaquiline.

The late involvement of public actors in the development of bedaquiline has not been framed within appropriate Public Private Partnerships (PPPs)/Product Development partnerships (PDPs), where ideally the entities taking part in product development obtain an upfront agreement on the future availability and accessibility of the medicine. Several examples show that PPPs/PDPs can be established on very weak terms in relation to pricing and access to the resulting product, hence with little reward to public investment. This approach would have additional limitations in the case of multiple public actors involved in different trials with the purpose of defining a shorter and more effective regimen, as for bedaquiline. Only one agreement is reported between Janssen and one of the trial sponsors. (3,7) The pull incentives granted by the US government for development of bedaquiline as an orphan and neglected tropical disease medicine and eventual agreements with trial sponsors did not have any impact beyond the tiered pricing applied by the company. (5) A recent systematic review intended to assess the functioning and impact of PPPs/PDPs for new health technologies for neglected tropical medicines revealed a clear lack of empirical assessment of PPPs/PDPs (10). Public funded incentives and late stage public investments for the development of shorter more effective regimens for DR-TB are failing to ensure availability and accessibility of this life-saving medicine.

The bedaquiline story once again raises the question: who rewards public investments on product development? Do public actors have the means to legally claim rights over their investment and contribution to innovation? Under which existing governance system and jurisdiction?

 

REFERENCES

  1. Rapid Communication: Key changes to treatment of multidrug- and rifampicin-resistant tuberculosis (MDR/RR-TB), World Health Organization, Geneva, August 2018. http://www.who.int/tb/publications/2018/WHO_RapidCommunicationMDRTB.pdf?ua=1
  2. WHO treatment guidelines for multidrug- and rifampicin-resistant tuberculosis, 2018 update, World Health Organization, Geneva, December 2018. https://www.who.int/tb/publications/2018/WHO.2018.MDR-TB.Rx.Guidelines.prefinal.text.pdf
  3. Milani B, A pipeline analysis of new products for malaria, tuberculosis and neglected tropical diseases: A Working Paper, United Nations Development Programme, August 2016. http://adphealth.org/upload/resource/ADP_Pipeline_Analysis_Report.pdf
  4. Clinical trials data on bedaquiline Phase II and III trials were collected through: https://clinicaltrials.gov
  5. The price of bedaquiline, Treatment Action Group, October 2018. http://www.treatmentactiongroup.org/sites/default/files/reality_check_bedaquiline_10_16_18.pdf
  6. Open Letter to J&J: Calling for affordable access to critical TB drug bedaquiline, MSF Access Campaign, September 2018. https://msfaccess.org/open-letter-jj-calling-affordable-access-critical-tb-drug-bedaquiline
  7. A review of the bedaquiline patent landscape, Unitaid, 2014. http://unitaid.org/assets/TMC_207_Patent_Landscape.pdf
  8. Updated patent landscape for bedaquiline available MedsPaL: https://www.medspal.org/?product_standardized_name%5B%5D=Bedaquiline+100+mg&page=1
  9. TB activists for first time challenge TB drug patent in India, in bid to prevent J&J from extending monopoly, Press release, MSF, February 2019 https://msfaccess.org/tb-activists-first-time-challenge-tb-drug-patent-india
  10. Aerts C, Sunyoto T, Tediosi F, Sicuri E. Are public-private partnerships the solution to tackle neglected tropical diseases? A systematic review of the literature. Health Policy. 2017 Jul;121(7):745-754. doi: 10.1016/j.healthpol.2017.05.005. Epub 2017 May 19.

 

 

 

It’s Time to End TB in EECA

Within the European region, most new TB cases and deaths are found in the Eastern European and Central Asian (EECA) countries. In this region we face an increasing number of drug resistant TB cases which becomes a real concern for patients and public health. AFEW Network is helping to eliminate tuberculosis in EECA

By Helena Arntz and Olesya Kravchuk

AFEW International

It’s Time to End Tuberculosis in Eastern Europe and Central Asia

 

24th of March marks World Tuberculosis day. The mortality rate of tuberculosis (TB) continues to decrease, but it is still one of the top 10 causes of death worldwide. According to the World Health Organization (WHO), TB caused 1.7 million deaths in 2017. Within the European region, most new TB cases and deaths are found in the Eastern European and Central Asian (EECA) countries. In this region we face an increasing number of drug resistant TB cases which becomes a real concern for patients and public health.

Countries in the Eastern part of the WHO European Region are most affected by the TB epidemic: 18 high-priority countries for TB control bear 85% of the TB burden, and 99% of the multidrug-resistant TB (MDR-TB) burden. These countries are Armenia, Azerbaijan, Belarus, Bulgaria, Estonia, Georgia, Kazakhstan, Kyrgyzstan, Latvia, Lithuania, the Republic of Moldova, Romania, the Russian Federation, Tajikistan, Turkey, Turkmenistan, Ukraine and Uzbekistan. Despite much progress in Eastern Europe, critical challenges remain as regards access to appropriate treatment regimens, patient hospitalisation, scale-up of laboratory capacity, including the use of rapid diagnostics and second-line Drug Susceptibility Testing (DST), vulnerable populations human resources, and financing.

AFEW Network is helping to eliminate tuberculosis in EECA. AFEW Kazakhstan together with KNCV in the Improved TB/HIV prevention & care – building models for the future project is increasing access to TB treatment. A model for effective partnership between government and public sectors of health care and organisations of civil society that provide TB-HIV services in Almaty, Kazakhstan is being developed. Within the Fast-Track TB/HIV Responses for Key Populations in EECA Cities project, AFEW Kazakhstan is piloting the innovative model of increasing the participation of the city administration in programs for the prevention and treatment of HIV infection and tuberculosis in the city of Almaty with particular emphasis on key populations. Within this program, models of sustainable city responses to HIV and TB in key population in EECA that significantly contribute to achieving 90-90-90 HIV/TB targets for key populations are being developed. The program is working in Bulgaria (Sofia), Georgia (Tbilisi), Kazakhstan (Almaty), Moldova (Balti), Ukraine (Odesa).

This year’s International TB Day’s theme is “IT’S TIME”. This slogan is indicating that it is time to end tuberculosis. There is a number of events that will draw attention to this day in Eastern Europe and Central Asia. The youth community center “Compass” in Kharkiv, Ukraine will hold a training session on the prevention of TB in one of the schools they work. Local NGOs in Kazakhstan have been providing tuberculosis screening in the shopping malls and markets before the World TB Day and were raising awareness of the disease within the students and migrants.

 

 

Turbulences in Uganda’s Global Aid Construct

At a time when to care about Uganda’s health system a model shift is required to be drawn for the coverage and effectiveness of aid to yield more productive results, this paper scrutinizes the changes, the form, and the applicability of external financing for health to Uganda and evaluates the level of influence of new alternatives available for health sector development

By Michael Ssemakula

Health Rights Advocate

Human Rights Research Documentation Center (HURIC), and PHM-Network, Uganda

Turbulences in Uganda’s Global Aid Construct

Is the Contemporary Aid Effective Enough to Transform Uganda’s Health System to Achieve UHC?

 

Over the last sixty-two years, Africa land mass has received an enormous share of foreign aid of over one-trillion US-Dollars (USD). This has intently been given to fight absolute poverty, hunger, and disease, humanitarian causes such as addressing internal conflicts, child labor and human trafficking to lessen the contemporary cross-Atlantic slave trade, and debt reliefs through the multi-lateral debt relief initiatives to expand the fiscal spaces of the resource poor countries especially in the sub-Saharan Africa, the world’s poorest region. Uganda in a particular has been in position to improve its health through Development Assistance for Health (DAH) for activities within health sector such as population programmes and Health Development Aid (HDA) from external resources in form of financial or in-kind aid that is directed to fund health-allied activities such as water and sanitation programmes (F, 2016). But, the disease burden continues to thrive in Uganda despite of all the multi-million dollar donations from external assistance for health.

The paper scrutinizes the changes, the form, and the applicability of external financing for health to Uganda and evaluates the level of influence of new alternatives available for health sector development. Aid has been contracted significantly for health sector projects’ support and enhancing national budget expenditures towards health to expand our fiscal space and attain the Sustainable Development Goals’ agenda…. which are supposed to guide countries to improve their health and development at large, to leave no one behind. But grants and loans given to accelerate health accessibility and poverty reduction programs have shown low propensity in health sector improvement. Case in line, Mulago Specialized Women and Neonatal Health Hospital in Uganda was renovated partly through the support of the donor’s aid to improve reproductive and maternal health services, but it has continued to set exorbitant fees for patients to access health thus expanding the inequality gap in accessing health in impoverished communities, and worsening the public decry, according to a report by (Atwine, 2018).  Over eras-of-time, health has been renowned to be a significant component for Gross Domestic Product (GDP) growth and economic development as a populace in good health can raise the productivity and efficiency of the State’s labor force while plummeting poverty. Therefore it is imperative to view access to good adequate health as a fundamental basic human right enshrined in the international covenant on social economic and cultural rights, a fulfillment and global commitment for both developed and countries in low-levels of economic transition.

Uganda needs approximately USD 15 billion to achieve affordable, acceptable and accessible health for all Ugandans through well planned holistic pre-payment mechanisms such as the National Health Insurance Scheme and Uganda National Minimum Health Care Package in our health system that can cover all citizens in their diverse income stratas. This comes at the time when donor environment over time has reformed the mechanisms through which they fund programmes. In Uganda, Structural Adjustment Programmes and State Wide Approaches were widely applied in many sectors like health and education (which were centralized systems of funding that circled macroeconomic policies in their operations such as retrenchment policies, liberalization and privatization drives to make state governments more efficient), to now project based form of funding which has been incorporated in projects like Global Financing Facility of the World Bank group and European Union Emergency Trust Fund for Africa (EUTF). All these models have been designed by the donor communities and the recipient state governments to improve health systems and infrastructure developments in the resource limited settings like Uganda, but the inequality gap in health accessibility does not correlate with the amount of aid pumped into the countries’ health sectors and other health-related activities to achieve Universal Health Coverage (UHC). The state is nevertheless the chief actor in the strengthening of the development assistance for health processes to maximize the health outcomes. Therefore the link between donors and state’s health sector should be purely interpreted as a cordial relationship formed to increase free-of-cost health service provision, through establishment of a strong health infrastructural system and well streamlined strategy for the proper utilization of development aid assistance.

Uganda has applied a queue of health development strategies and policies such as the Health Sector Development Plans and so many others to improve health with more than 45% dependence on aid from donors, foundations, philanthropists, and non-government organizations (Health, 2014/15 & 2015/16). The state of poor health system in Uganda and other countries in the East African bloc amidst the increasing donor funding is attributed to a multiplicity of factors. Research shows the contemporary aid given in most of times is largely shrouded with donor interests. Further, it is being taken as a conduit for expansion of influence and conglomerates of the multinational private companies especially the pharmaceutical corporations; this is because many of these leverage on the partnerships they have with the global financing trust funds through contract provision of certain services such as, infrastructure development, medicines and technologies. They eventually price their services or health products so highly thereby enlarging the health accessibility disparity in the vulnerable communities, which is contrary to the principles of public health. Unendurable conditionalities are part of the mix in the aid construct which in most cases are hard to meet to yield the desired results. For instance, the Global Financing Facility (GFF´s) Results-Based Financing (RBF) model in its monitoring framework which focuses on specific indicators to determine fund disbursement at health facility and district level has been encircled with many inadequacies in Uganda.  The approach is meant to increase the motivation of healthcare workers and the financial autonomy of healthcare facilities, in order to improve performance of health systems and ultimately improve the health outcomes. However, emerging evidence of this financing approach reveals an irregular performance record. In adding, the broad implementation of RBF across a feeble or unprepared health care system raises many concerns. Experience shows that health facilities with existing poor performance levels will simply not succeed in creating a sufficient inflow of funds through RBF mechanism. Struggling health centres failing to reach RBF targets risk penalization through aid-cuts for failure to meet the set targets as part of the conditionalities in this funding modality, thereby demoralizing health workers and creating greater inequity as these health centres and the populations they serve are left behind, (Paul E, 2018).

Apparently, NGOs and the third-sector which are essentially the second engine of the health sector functioning in Uganda have a remarkable role to play as their sovereignty and self-sufficiency raises above the state’s; this is reflected through the variance in support towards the health sector by the government and the donor community. Uganda has experienced so many periods of incapacity to meet the required global financing commitments to health to provide its primary health care services to the society, which has prompted the donors (internally and externally) and lenders of all sorts to intervene through credits, grants, aid and others. Aid given to economies in transition such as those in the great-lakes region of Africa, is majorly destined to assist these states to undertake and complete their health and development projects. These aids usually come from the ex-colonial monopole and partnership financing initiatives to fortify bilateral-ties and advance donor interests. In sub-Saharan Africa, foreign aid now comes in numerous forms but the most common one is through partnership trust funds like Global fund, Global Alliance for Vaccines and Immunizations (GAVI); International Monetary Fund (IMF) through World Bank Group, European Union Emergency Trust Fund for Africa, and Global Financing Facility of the World Bank Group. These support projects that involve investment in health (such as advancing Primary Health Care, health infrastructure development and health system upgrade: case in line Uganda upgraded health centres in 2018 in different levels to revive its referral system), technical assistance of the various projects, budget support, debt reliefs through multilateral debt relief initiatives; not to mention investing in people to harness better social welfare provision and improve our Human Development Index, bio-diversity protection and climate change, support to non-state institutions involved in the human development and humanitarian causes, food security, migration problems, and so on. However, due to the dynamics in the contemporary aid, a lot of inadequacies surround aid given. There is always a lacuna in its effectiveness, delays and postponements in execution of projects due to aid’s volatility and unpredictability.

Currently, most of the aid financing modalities intends to leverage on lending. For instance, the Global Financing Facility project on Reproductive Maternal Newborn Child and Adolescent Health and Nutrition (RMNCAH+N), being implemented in Uganda and other sub-Saharan Africa states, links its grant money to World Bank lending. At the onset, an average of USD $1 of a GFF grant was matched with USD $4 of a World Bank loan. Three-years ahead, this fraction has almost doubled, ascending to USD $1: USD $7. With several GFF eligible and qualified countries already worryingly and severely indebted, additional increases in nation’s indebtedness are troubling. In the long-term, such heavy dependence on credit risks forming untenable loan repayment burdens. If the countries prioritize the servicing of these debts, this may force governments into resolutions to cut their spending in other areas, such as indispensable essential social services. Ultimately, this undermines or weakens health systems.

Conclusion and Recommendation

To care about our health system, a model shift is required to be drawn for the coverage and effectiveness of aid in Uganda to yield more productive results. Therefore close monitoring of aid especially in form of credit both short- and long-term effects is crucial. In countries such as Uganda where the risks of debt increases are deemed high, aid structures need to be revised and implement measures to protect the delivery of essential health services for the long-term. Establishment of strong robust evaluation mechanisms, and adaptation of design and implementation modalities is required. This can be backed by continuing a thorough and transparent review of health and equity outcome data under performance-centric schemes on aid effectiveness.

 

References

Atwine, A. (2018). Public anger as Govt sets exorbitant charges for new Mulago women hospital. Kampala: daily post Uganda.

F, N. (2016). Failure of Foreign Aid in Developing Countries: A Quest for Alternatives. Accra: Business and Economics Journal.

Health, M. o. (2014/15 & 2015/16). National Health Expenditure. Kampala: Ministry of Health.

Paul E, A. L. (2018). Performance-based financing in low-income and middle-income countries: isn’t it time for a rethink? BMJ global health, pg e000664.